Table 1 Demographic and clinical characteristics of enrolled patients (n = 39)
Patient characteristics | n (%) |
|---|---|
Median age (years) | 76.7 (range 39–96) |
Gender: female/male | 8 (20.5)/31 (79.5) |
CNS metastases at baseline | 5 (12.2) |
Type of anti-PD-1 agent | |
Cemiplimab | 39 (100) |
Line of treatment | |
Frist-line treatment | 28 (71.8) |
Second-line treatment | 11 (28.2) |
Type of previous therapy | |
Radiotherapy | 9 (81.8) |
Targeted therapy | 1 (9.1) |
Immunotherapy | 1 (9.1) |
Response rate at first assessment | |
Partial response | 15 (38.5) |
Stable disease | 10 (25.6) |
Progression disease | 14 (35.9) |
Objective response rate | 15 (38.5) |
Disease control rate | 18 (46.1) |
BORR | 17 (44%) |
Therapies after PD | |
BSC | 16 (41) |
chemotherapy | 3 (8) |
Lost follow up | 3 (8) |
Comorbidities | |
Myocardial infarction | 2 (5) |
Angina/coronary artery disease | 12 (31) |
Arrhythmias | 9 (23) |
Hypertension | 25 (64) |
Respiratory system | 1 (3) |
Hepatic | 2 (5) |
Renal system | 4 (10) |
Diabetes | 8 (21) |
Neuromuscular disease | 1 (3) |
Malignancy: leukemia and myeloma | 2 (5) |
Malignancy: other cancers | 8 (12) |
Benign prostatic hyperplasia | 4 (10) |
Dyslipidemia | 9 (23) |